Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avai BioAVAI +5.31%24 Cash-to-Debt is 0.03 as of Dec. 2025, which is at its 10-year median of 0.03. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 2,852 Software companies, Avai Bio ranks worse than 97.12% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Avai Bio's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.03.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Avai Biocouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Avai Bio's Cash-to-Debt or its related term are showing as below:
AVAI'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 1.2
Current: 0.03
During the past 8 years, Avai Bio's highest Cash to Debt Ratio was 1.20. The lowest was 0.00. And the median was 0.03.
AVAI's Cash-to-Debt is ranked worse than 97.12% of 2852
companies
in the Software industry
Industry Median: 2.51
vs AVAI: 0.03
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Avai Bio Cash-to-Debt Related Terms
Avai Bio Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Avai Bio's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Software - Application subindustry, Avai Bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avai Bio Cash-to-Debt vs Software Industry
For the Software industry and Technology sector, Avai Bio's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Avai Bio's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avai Bio (AVAI) has a Cash-to-Debt of 0.03 as of Dec. 2025. This is near median its historical median of 0.03. According to the industry distribution chart, Avai Bio ranks #2770 out of 2852 companies in the Software industry, placing it in the top 97.1%.
Is Avai Bio's Cash-to-Debt too high?
Avai Bio's current Cash-to-Debt of 0.03 is near median its 10-year median of 0.03. The Software industry median Cash-to-Debt is 2.51. Avai Bio's value of 0.03 is 98.8% below this industry median. Based on the distribution chart, Avai Bio ranks #2770 out of 2852 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's Cash-to-Debt compare to IPM and CRMZ?
According to the Software industry distribution chart, Avai Bio ranks #2770 out of 2852 companies for Cash-to-Debt. This places Avai Bio in the lower half of its industry. The industry median Cash-to-Debt is 2.51. Avai Bio's value of 0.03 is 98.8% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 2.51, Avai Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Software company?
The median Cash-to-Debt among Software companies is 2.51, based on 2,852 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avai Bio's current Cash-to-Debt of 0.03 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Software industry, the median Cash-to-Debt is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avai Bio's current Cash-to-Debt is 0.03, which is near median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current Cash-to-Debt of 0.03. The current Cash-to-Debt is 0.03, which is near median its 10-year median of 0.03 and 98.8% below the Software industry median of 2.51. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Avai Bio (AVAI), the current Cash-to-Debt is 0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score
Get the complete analysis for AVAI
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVAI has been successfully added to your 
